ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2014
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 118 citations in OpenAlex.
- Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.Leukemia · 2018Trial
- Mast cell leukemia with complex genomic alterations in an elderly patient with prior hematologic and solid malignancies: a case report.Annals of medicine and surgery (2012) · 2026Article
- Diagnosing Systemic Mastocytosis: State of the Art.International journal of laboratory hematology · 2026Review
- Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.American journal of hematology · 2025Review
- French guidelines for the management of nonadvanced mastocytosis in adults.Orphanet journal of rare diseases · 2025Article
- Systemic mastocytosis: current status and challenges in 2024.Blood advances · 2025Review
- Mastocytosis.Nature reviews. Disease primers · 2025Review
- Case report: Experience of a rare case of primary acute mast cell leukemia.Leukemia research reports · 2025Article
- Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype,Haematologica · 2024Article
- Review
- Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome inCancers · 2024Article
- Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis.Case reports in hematology · 2024Article
- Review
- Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.International journal of molecular sciences · 2023Review
- Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.Blood advances · 2023Article
- Engraftment in NSGLeukemia · 2023Article
- Mast Cell Leukemia: An Update with a Practical Review.Cancers · 2023Review
- Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.Cytometry. Part B, Clinical cytometry · 2023Article
- Article
- Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 20 institutions in 10 countries.
Funding
Abstract
Mast cell leukemia (MCL), the leukemic manifestation of systemic mastocytosis (SM), is characterized by leukemic expansion of immature mast cells (MCs) in the bone marrow (BM) and other internal organs; and a poor prognosis. In a subset of patients, circulating MCs are detectable. A major differential diagnosis to MCL is myelomastocytic leukemia (MML). Although criteria for both MCL and MML have been published, several questions remain concerning terminologies and subvariants. To discuss open issues, the EU/US-consensus group and the European Competence Network on Mastocytosis (ECNM) launched a series of meetings and workshops in 2011-2013. Resulting discussions and outcomes are provided in this article. The group recommends that MML be recognized as a distinct condition defined by mastocytic differentiation in advanced myeloid neoplasms without evidence of SM. The group also proposes that MCL be divided into acute MCL and chronic MCL, based on the presence or absence of C-Findings. In addition, a primary (de novo) form of MCL should be separated from secondary MCL that typically develops in the presence of a known antecedent MC neoplasm, usually aggressive SM (ASM) or MC sarcoma. For MCL, an imminent prephase is also proposed. This prephase represents ASM with rapid progression and 5%-19% MCs in BM smears, which is generally accepted to be of prognostic significance. We recommend that this condition be termed ASM in transformation to MCL (ASM-t). The refined classification of MCL fits within and extends the current WHO classification; and should improve prognostication and patient selection in practice as well as in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.